133 related articles for article (PubMed ID: 24092864)
61. Distinct Antiviral Potency of Sofosbuvir Against Hepatitis C and E Viruses.
Wang W; Hakim MS; Nair VP; de Ruiter PE; Huang F; Sprengers D; Van Der Laan LJ; Peppelenbosch MP; Surjit M; Pan Q
Gastroenterology; 2016 Dec; 151(6):1251-1253. PubMed ID: 27815000
[No Abstract] [Full Text] [Related]
62. Modeling the antiviral activity of ribavirin against hepatitis C virus in cell culture.
Felmlee DJ; Xiao F; Baumert TF
Hepatology; 2013 Oct; 58(4):1203-6. PubMed ID: 23703706
[No Abstract] [Full Text] [Related]
63. Curcumin inhibits bovine herpesvirus type 1 entry into MDBK cells.
Zhu L; Ding X; Zhang D; Yuan Ch; Wang J; Ndegwa E; Zhu G
Acta Virol; 2015 Sep; 59(3):221-7. PubMed ID: 26435144
[TBL] [Abstract][Full Text] [Related]
64. Occludin-binding single-chain variable fragment and antigen-binding fragment antibodies prevent hepatitis C virus infection.
Shimizu Y; Shinoda T; Shirasago Y; Kondoh M; Shinya N; Hanada K; Yagi K; Suzuki T; Wakita T; Kimura-Someya T; Shirouzu M; Fukasawa M
FEBS Lett; 2021 Jan; 595(2):220-229. PubMed ID: 33113151
[TBL] [Abstract][Full Text] [Related]
65. Hepatocyte proliferation and hepatitis C virus kinetics during treatment.
Dahari H; Rong L; Layden TJ; Cotler SJ
Clin Pharmacol Ther; 2011 Mar; 89(3):353-4. PubMed ID: 21270791
[No Abstract] [Full Text] [Related]
66. Prevention of HCV replication by serine palmitoyltransferase inhibition.
Lowe AW; Moseley RH
Gastroenterology; 2013 Oct; 145(4):701-2. PubMed ID: 24187689
[No Abstract] [Full Text] [Related]
67. A summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses.
Beard MR; Ffrench R; Gowans EJ; Helbig KJ; Eyre NM; Douglas MM; Grebely J; Ahlenstiel G; Locarnini S; George J; Shackel NA; White PA; Thompson AJ; Drummer HE
Gastroenterology; 2014 Jul; 147(1):e1-4. PubMed ID: 24861641
[No Abstract] [Full Text] [Related]
68. [Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012].
Sarrazin C; Zimmermann T; Berg T; Neumann UP; Schirmacher P; Schmidt H; Spengler U; Timm J; Wedemeyer H; Wirth S; Zeuzem S; ; ; ; ; ; ; ; ; ; ; ; ; ;
Z Gastroenterol; 2018 Jul; 56(7):756-838. PubMed ID: 29945279
[No Abstract] [Full Text] [Related]
69. Regulating interferon antiviral activity: a role for epidermal growth factor receptor.
Schoggins JW
Hepatology; 2013 Oct; 58(4):1200-2. PubMed ID: 23703779
[No Abstract] [Full Text] [Related]
70. Plugging the holes in hepatitis C virus antiviral therapy.
Griffin SD
Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12567-8. PubMed ID: 19666619
[No Abstract] [Full Text] [Related]
71. Finding the balance: the role of S-adenosylmethionine and phosphatidylcholine metabolism in development of nonalcoholic fatty liver disease.
Jacobs RL; van der Veen JN; Vance DE
Hepatology; 2013 Oct; 58(4):1207-9. PubMed ID: 23703836
[No Abstract] [Full Text] [Related]
72. Chemical Synthesis Enables Structural Reengineering of Aglaroxin C Leading to Inhibition Bias for Hepatitis C Viral Infection.
Zhang W; Liu S; Maiga RI; Pelletier J; Brown LE; Wang TT; Porco JA
J Am Chem Soc; 2019 Jan; 141(3):1312-1323. PubMed ID: 30590924
[TBL] [Abstract][Full Text] [Related]
73. Virology: Final entry key for hepatitis C.
Pietschmann T
Nature; 2009 Feb; 457(7231):797-8. PubMed ID: 19212389
[No Abstract] [Full Text] [Related]
74. Flunarizine arrests hepatitis C virus membrane fusion.
Prigozhin DM; Modis Y
Hepatology; 2016 Jan; 63(1):14-6. PubMed ID: 26389725
[No Abstract] [Full Text] [Related]
75. Antiviral activity of Inonotus obliquus fungus extract towards infection caused by hepatitis C virus in cell cultures.
Shibnev VA; Mishin DV; Garaev TM; Finogenova NP; Botikov AG; Deryabin PG
Bull Exp Biol Med; 2011 Sep; 151(5):612-4. PubMed ID: 22462058
[TBL] [Abstract][Full Text] [Related]
76. Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations.
Padmanabhan P; Dixit NM
Proc Natl Acad Sci U S A; 2017 Jun; 114(23):E4524-E4526. PubMed ID: 28512229
[No Abstract] [Full Text] [Related]
77. The development of anti-hepatitis C virus agents.
Shimotohno K
Hepatology; 1995 Mar; 21(3):887-8. PubMed ID: 7875689
[No Abstract] [Full Text] [Related]
78. The road to hepatitis C virus elimination.
Cotte L; Pradat P
Lancet Public Health; 2023 Apr; 8(4):e254. PubMed ID: 36965979
[No Abstract] [Full Text] [Related]
79. [The guideline of prevention and treatment for hepatitis C: a 2015 update].
; Wei L; ; Hou JL
Zhonghua Gan Zang Bing Za Zhi; 2015 Dec; 23(12):906-23. PubMed ID: 26739465
[No Abstract] [Full Text] [Related]
80. New hepatitis C antiviral treatments eliminate the virus.
Doyle JS; Thompson AJ; Higgs P; Stoove M; Dietze PM; Hellard ME
Lancet; 2017 Jul; 390(10092):358-359. PubMed ID: 28689663
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
